Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 68
GLP-1 agonists and cardiac catheterization
A July 2026 study examines whether patients can safely continue semaglutide or tirzepatide before cardiac catheterization with moderate sedation.
GLP-1 drugs and mitochondria: a 2026 review
A 2026 meta-analysis found GLP-1 agonists improved bioenergetics and cut oxidative stress in human cell models, but rated the evidence certainty as very low.
Hengrui HRS-7535 oral GLP-1: Phase 3 data
Hengrui and Kailera reported Phase 3 results for HRS-7535, an oral GLP-1 drug, in July 2026. Here is what the peer-reviewed Phase 2 data shows.
Who shapes Mounjaro talk on X? Not doctors
A July 2026 study found non-medical accounts, not clinicians, drive Mounjaro (tirzepatide) talk on X. What the network data shows.
Semaglutide and bilateral NAION
A July 2026 case report describes bilateral NAION and branch retinal artery occlusion in a man on semaglutide, with partial visual recovery after stopping.
Semaglutide: dose predicts CV outcomes
A July 2026 study found semaglutide's heart benefits track dose more closely than weight loss.
GLP-1 drugs: fewer falls in older adults
Semaglutide and tirzepatide were associated with roughly half the femoral fracture rate versus DPP-4 inhibitors in older adults with type 2 diabetes.
What Semax costs in the Netherlands
Semax has no EMA or CBG-MEB authorisation, so there is no official Dutch pharmacy price and no GVS reimbursement. Here is what that means for Dutch readers.
TAAR1: the metabolic target after GLP-1
A 2026 review argues TAAR1 shares key mechanisms with GLP-1 agonists and may reach aspects of metabolic disease that semaglutide addresses only indirectly.
Tirzepatide vs semaglutide: JASSO subgroup
SURMOUNT-5 subgroup: tirzepatide cut body weight by 20.1% vs 12.9% for semaglutide in 383 adults meeting Japan obesity disease criteria.
Why Dr. Reddy's paused generic semaglutide
Dr. Reddy's paused generic semaglutide after flagging an API quality issue. Here is what that means for patients, prescribers, and the generic GLP-1 market.
GLP-1 drugs, menstrual changes: FAERS 2026
A July 2026 FAERS study found semaglutide carries broader menstrual signals than tirzepatide or liraglutide, but the data cannot establish causation.